Potential New Treatment for Alpha-1 Antitrypsin Deficiency


Trial Objective

Potential New Drug Alvelestat for AATDResearchers want to see if a new drug, alvelestat, improves the symptoms of lung disease caused by COPD due to alpha-1 antitrypsin deficiency (AATD), as well as symptoms of the AATD.


Active Clinical Trials Currently Recruiting

Who Can Participate

People between the ages of 18-80 with chronic obstructive pulmonary disease (COPD) due to alpha-1 antitrypsin deficiency (AATD) may be eligible to participate.

Age: 18-80    Gender: Any Gender

Estimated Time Commitment

Up to 5 months

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Kristina Eliopoulos

Kristina Eliopoulos

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

National Institutes of Health, University of Alabama at Birmingham


Request More Information

By completing this form, you agree to learn more about this study and see if you qualify.

 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: